Mucosal Immunization with a Urease B DNA Vaccine Induces Innate and Cellular Immune Responses Against Helicobacter pylori

Helicobacter ◽  
2006 ◽  
Vol 11 (2) ◽  
pp. 113-122 ◽  
Author(s):  
Caterina Hatzifoti ◽  
Yvonne Roussel ◽  
Andrew G. Harris ◽  
Brendan W. Wren ◽  
John W. Morrow ◽  
...  
Vaccine ◽  
2016 ◽  
Vol 34 (32) ◽  
pp. 3634-3640 ◽  
Author(s):  
Marie Borggren ◽  
Jens Nielsen ◽  
Ingrid Karlsson ◽  
Tina S. Dalgaard ◽  
Ramona Trebbien ◽  
...  

Vaccine ◽  
2008 ◽  
Vol 26 (49) ◽  
pp. 6225-6231 ◽  
Author(s):  
Krystle A. Lang ◽  
Jian Yan ◽  
Ruxandra Draghia-Akli ◽  
Amir Khan ◽  
David B. Weiner

Vaccine ◽  
2005 ◽  
Vol 23 (14) ◽  
pp. 1649-1656 ◽  
Author(s):  
He Xiao-wen ◽  
Sun Shu-han ◽  
Hu Zhen-lin ◽  
Li Jun ◽  
Jiang Lei ◽  
...  

2001 ◽  
Vol 69 (2) ◽  
pp. 1025-1031 ◽  
Author(s):  
Kathryn A. Eaton ◽  
Megan E. Mefford

ABSTRACT Vaccination suppresses Helicobacter pylori colonization but does not cure infection. Furthermore, postvaccination gastritis, likely induced by enhanced host response to residual colonization, may exacerbate disease. The goal of this study was to determine if adoptive transfer of C57BL/6 splenocytes to C57BL/6scid/scid (severe combined immunodeficient [SCID]) mice cures infection without exacerbating gastritis. H. pylori-infected and uninfected C57BL/6 mice and SCID recipients of normal splenocytes were killed at intervals between 5 and 51 weeks after infection. Colonization and gastritis were quantified, humoral immune responses were determined by enzyme-linked immunosorbent assay, and cellular immune responses were determined by delayed-type hypersensitivity response and by a proliferative response of cultured splenocytes to H. pylorisonicate. In infected C57BL/6 mice, gastritis developed gradually and bacterial colonization diminished but persisted throughout the experiment. In contrast, gastritis in infected recipient SCID mice developed rapidly and bacterial colonization decreased precipitously. Gastritis in those mice peaked 9 weeks after adoptive transfer, however, and began to resolve. By 45 weeks after transfer, gastritis had returned to background levels and bacteria were no longer detectable. Resolution of gastritis and elimination of infection were associated with a cellular but not humoral immune response to H. pylori antigens. These results demonstrate that although the host response fails to clear bacterial colonization in normal mice, enhanced cellular immune responses in recipient SCID mice are capable of clearing H. pylori infection and allowing resolution of gastritis. Thus, immune mechanisms of cure exist, and effective and safe vaccination protocols may be feasible.


2017 ◽  
Vol 27 (3) ◽  
pp. 168-174 ◽  
Author(s):  
Yu Yang ◽  
Zhiqiang Shao ◽  
Jiangping Gao

To improve the lower immune intensity of DNA vaccines, we developed a DNA vaccine based on prostate cancer-specific antigen (PSA), which has been suggested as a potential target for prostate cancer therapy, and enhanced the DNA vaccine potency using interleukin-12 (IL-12) as an intramolecular adjuvant. A series of DNA plasmids encoding human PSA, IL-12, and their conjugates was constructed and injected into female mice intramuscularly, followed by an electric pulse. The humoral and cellular immune responses after immunization were detected by ELISA and ELISPOT, respectively. To evaluate the therapeutic efficacy of these plasmids, a mouse model with a PSA-expressing tumor was constructed. Mice vaccinated with PSA-IL-12 plasmids elicited the strongest PSA-specific humoral and cellular immune responses. Furthermore, these vaccinations inhibited the growth of PSA-expressing tumors and prolonged mouse survival. These observations emphasize the potential of the IL-12 gene as an intramolecular adjuvant for DNA vaccines. Moreover, the vaccine based on PSA and IL-12 may be a promising treatment for prostate cancer.


2004 ◽  
Vol 23 (5) ◽  
pp. 335-339 ◽  
Author(s):  
Hongxuan He ◽  
Baohua Zhao ◽  
Liyan Liu ◽  
Kai Zhou ◽  
Ximing Qin ◽  
...  

2014 ◽  
Vol 10 (8) ◽  
pp. 2357-2365 ◽  
Author(s):  
Brian Latimer ◽  
Roberta Toporovski ◽  
Jian Yan ◽  
Panyupa Pankhong ◽  
Matthew P Morrow ◽  
...  

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 852
Author(s):  
Khalid A. Alluhaybi ◽  
Rahaf H. Alharbi ◽  
Rowa Y. Alhabbab ◽  
Najwa D. Aljehani ◽  
Sawsan S. Alamri ◽  
...  

The urgent need for effective, safe and equitably accessible vaccines to tackle the ongoing spread of COVID-19 led researchers to generate vaccine candidates targeting varieties of immunogens of SARS-CoV-2. Because of its crucial role in mediating binding and entry to host cell and its proven safety profile, the subunit 1 (S1) of the spike protein represents an attractive immunogen for vaccine development. Here, we developed and assessed the immunogenicity of a DNA vaccine encoding the SARS-CoV-2 S1. Following in vitro confirmation and characterization, the humoral and cellular immune responses of our vaccine candidate (pVAX-S1) was evaluated in BALB/c mice using two different doses, 25 µg and 50 µg. Our data showed high levels of SARS-CoV-2 specific IgG and neutralizing antibodies in mice immunized with three doses of pVAX-S1. Analysis of the induced IgG subclasses showed a Th1-polarized immune response, as demonstrated by the significant elevation of spike-specific IgG2a and IgG2b, compared to IgG1. Furthermore, we found that the immunization of mice with three doses of 50 µg of pVAX-S1 could elicit significant memory CD4+ and CD8+ T cell responses. Taken together, our data indicate that pVAX-S1 is immunogenic and safe in mice and is worthy of further preclinical and clinical evaluation.


Sign in / Sign up

Export Citation Format

Share Document